GSK announces that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International.

This aims to promote its development and distribution in low- and middle-income countries, where Shigella bacteria pose a major threat to children under five.

Interim results from phase 1 and 2 clinical trials have confirmed the potential of the vaccine, which uses GMMA (Generalized Modules for Membrane Antigens) technology, which is inexpensive and easily industrializable.

This collaboration is part of the fight against antimicrobial resistance, as the vaccine could indirectly reduce antibiotic consumption.GSK will support Bharat Biotech in designing the Phase 3 trial and seeking external funding.


Copyright (c) 2025 CercleFinance.com. All rights reserved.